image credit- shutterstock
US-based Flagship Pioneering, a bioplatform innovation company, the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine), National University Hospital (NUH) and the National University Health System (NUHS) have announced a research and development collaboration to advance outcomes in human health and sustainability. A Memorandum of Understanding (MoU) was signed by Flagship, NUS Medicine, NUH and NUHS outlining their collaboration goals.
Flagship, NUS Medicine, NUH and NUHS expect to create, co-develop and co-resource a series of research projects over an initial five-year horizon, tapping into opportunities across Flagship’s existing ecosystem of over 40 companies, and future companies founded by Flagship.
Through potential secondments, internships and participation in the Flagship Fellowship programme, the collaboration will also create career development and mentorship opportunities for scientists and students of NUS Medicine with Flagship.
In addition, Flagship will tap into the ecosystem of NUH and NUHS to leverage clinical data for new biological insights, test clinical hypotheses for novel impact and improved patient outcomes.
“Our collaboration with NUS Medicine, NUH and NUHS will help us realise our goal to expand the global reach and impact of Flagship and its companies and serve as an anchor in Singapore and throughout Asia Pacific for globally connected life science innovation. Along with our previously announced collaboration with the Agency for Science, Technology and Research (A*STAR), our work with NUS Medicine, NUH and NUHS has the potential to bring together key players across Singapore’s biotech ecosystem to advance breakthroughs that impact patients and the planet”, said said André Andonian, Chair of Asia Pacific and Strategic Advisor, Flagship Pioneering.
